NASDAQ · Biotechnology

NRIX (NRIX) Stock

$24.11 -0.17% NASDAQ: NRIX Healthcare

Valuation

MetricValue
Price$24.11
Market Cap$2.50B
P/E Ratio-6.41
P/B Ratio3.69
P/S Ratio20.75
EPS (TTM)$-2.86
52-Week High$24.91
52-Week Low$8.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-61.40%
ROA-31.50%
ROCE-53.06%
Gross Margin-1.39%
Operating Margin-4.39%
Net Margin-4.11%
Debt/Equity0.12
Current Ratio7.06

Annual Financials (USD)

Metric20212022202320242025
Revenue$30.0M$39.0M$77.0M$55.0M$84.0M
Operating Profit$-118.0M$-184.0M$-155.0M$-213.0M$-286.0M
Net Profit$-117.0M$-180.0M$-144.0M$-194.0M$-264.0M
EPS$-2.73$-3.71$-2.65$-2.88$-3.05
Op Margin-396.3%-476.0%-201.4%-390.5%-340.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$477.0M$417.0M$356.0M$669.0M$688.0M
Total Liabilities$134.0M$113.0M$155.0M$142.0M$149.0M
Cash$81.0M$64.0M$55.0M$110.0M$247.0M
Borrowings$13.0M$12.0M$31.0M$28.0M$56.0M

Latest News

Mizuho Raises Price Target on Nurix Therapeutics to $34 From $30, Keeps Outperform Rating MT Newswires · Jul 13, 2026 Company News for July 13, 2026 Zacks · Jul 13, 2026 Nurix Therapeutics' Roche Deal Seen Driving Long-Term Upside, RBC Capital Markets Says MT Newswires · Jul 10, 2026 Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates Zacks · Jul 9, 2026 Nurix Therapeutics Q2 Loss Widens, Revenue Falls MT Newswires · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-84.0M$-160.0M$-81.0M$-173.0M$-249.0M
Investing Cash Flow$-114.0M$15.0M$60.0M$-267.0M$134.0M
Financing Cash Flow$4.0M$98.0M$0$7.0M$0
Net Cash Flow$-39.0M$-15.0M$-10.0M$55.0M$137.0M
Free Cash Flow$-90.0M$-172.0M$-90.0M$-182.0M$-263.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-4.13
FCF Yield-18.25%
Quick Ratio6.01
Interest Coverage—
Return 1Y109.78%
Return 3Y134.36%
Return 5Y-23.18%

Ownership

Insiders Held1.08%
Institutions Held114.44%
Institutions Float Held115.69%
Institutional HolderSharesReport Date
Blackrock Inc.8,925,6422026-03-31
Redmile Group, LLC7,732,8082026-03-31
Vestal Point Capital, LP6,500,0002026-03-31
Deep Track Capital, Lp6,345,2442026-03-31
FMR, LLC5,541,2712026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BBOT $8.09 -4.82% -3.62 $648.07M 0.00%
EYPT $12.41 +1.80% -4.34 $1.04B 0.00%
FTRE $18.43 +4.18% -1.26 $1.75B 0.00%
KOD $41.58 -2.16% -8.11 $2.60B 0.00%
KURA $9.57 +3.13% -2.90 $849.57M 0.00%

About NRIX

NRIX is led by CEO Arthur T. Sands, employs 286 people, headquartered in US, publicly traded since 2020.

NRIX stock trades at $24.11 with a market capitalization of $2.50B. The stock is valued at a price-to-earnings (P/E) ratio of -6.41, price-to-book of 3.69, price-to-sales of 20.75. Over the past 52 weeks the stock has ranged between $8.20 and $24.91, and currently trades 3.2% below its 52-week high.

On profitability, NRIX generates a return on equity (ROE) of -61.40%, return on capital employed of -53.06%, an operating margin of -4.39%, a net profit margin of -4.11%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides